Author contributions Authors responsible for concept and design were MJH, HTL, HYH, YL, and JHSP
MAO inhibitors: High doses of MAO inhibitors combined with higher cerebrolysin dosages (30 ml or above) have been reported to increase blood pressure
There was one recurrence among patients who continued receiving sifalimumab
Funding This work was supported by grants from the National Natural Science Foundation of China (NSFC Numbers 81672800, 81603009, 81673020, 81802632, and 82173830), Natural Science Foundation of Shaanxi (2020JQ-445), and the Key Research and Development Program of Shaanxi Province (2021SF-207, 2021SF-223, and 2022ZDLSF05-19)
combination data is nonexistent Safety first Overlapping side effect profiles create legitimate concerns about additive adverse events Patience pays Phase 3 trials for both compounds are ongoing
Based on the available research conducted by Dr